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Pyruvate kinase (PK) deficiency is a rare recessive congenital hemolytic anemia caused by 
mutations in the PKLR gene. This study reports the molecular features of 257 patients enrolled in 
the PKD Natural History Study.  Of the 127 different pathogenic variants detected, 84 were  
missense and 43 non-missense, including 20 stop-gain codon, 11 affecting splicing, 5 large 
deletions, 4 in-frame indels, and 3 promoter variants. Within the 177 unrelated patients, 35 were 
homozygous and 142 compound heterozygous (77 for two missense, 48 for one missense and one 
non-missense, and 17 for two non-missense variants); the two most frequent mutations were 
p.R510Q in 23% and p.R486W in 9% of mutated alleles. Fify-five (21%) patients were found to 
have at least one previously unreported variant with 45 newly described mutations. Patients with 
two non-missense mutations had lower hemoglobin levels, higher numbers of lifetime transfusions, 
and higher rates of complications including iron overload, extramedullary hematopoiesis, and 
pulmonary hypertension. Rare severe complications, including lower extremity ulcerations and 
hepatic failure, were seen more frequently in patients with non-missense mutations or with 
missense mutations characterized by severe protein instability. PKLR genotype did not correlate 
with the frequency of complications in utero or in the newborn period. With ICCs ranging from 0.4-
0.61, about the same degree of clinical similarity exists within siblings as it does between siblings, 
in terms of hemoglobin, total bilirubin, splenectomy status, and cholecystectomy status. Pregnancy 
outcomes were similar across genotypes in PK deficient women. This report confirms the wide 
genetic heterogeneity of PK deficiency. 





Pyruvate kinase (PK) deficiency is the most frequent enzyme abnormality of the glycolytic 
pathway, and the most common cause of hereditary non-spherocytic hemolytic anemia. PK 
deficiency has a worldwide geographical distribution with an estimated prevalence ranging from 1-
5 per 100,000 in the Caucasian population; higher frequencies are present in the Pennsylvania 
Amish and the Roma communities as a result of a founder effect.1-4 Discrepancies exist between the 
published estimated prevalence and the lower prevalence suggested by data from patient registries 
and clinical practice, which may be explained by a high number of mildly affected undiagnosed 
patients and challenges in diagnosing PK deficiency.5  
 
Clinical manifestations of PK deficiency reflect the symptoms and complications of lifelong 
chronic hemolysis, including anemia, jaundice, bilirubin gallstones, splenomegaly, and iron 
overload6-9. The severity of symptoms is highly variable, ranging from mild anemia or fully 
compensated hemolysis to life-threatening anemia necessitating neonatal exchange transfusions 
and/or subsequent regular transfusion support.10-12  
 
PK deficiency is inherited in an autosomal recessive pattern and is caused by homozygous or 
compound heterozygous variants in the PKLR gene located on chromosome 1q21. 13   To date, more 
than 300 mutations in the PKLR gene have been reported 
(https://databases.lovd.nl/shared/genes/PKLR).8,11-15 The majority of these mutations are missense 
substitutions affecting residues critical to the structure and/or function of the enzyme, followed by 
frameshift and splicing mutations and premature stop codons; promoter variants and large 
insertions/deletions (indel) are rare. Recently, compound heterozygous variants with deep intronic 
mutations as a cause of PK deficiency have been reported.17  The most frequent mutations are 
distributed regionally: p.R510Q in Northern Europe and the United States, p.R486W in Southern 
Europe, and p.R490W in Japan.13  
 
Genotype-phenotype correlation in PK deficiency has been investigated through both clinical 
studies and by in vitro production and characterization of recombinant mutant proteins of human 
PK.18-20  These studies have suggested that patients with severe hemolytic anemia more commonly 
have deleterious mutations or missense pathogenic variants which affect the active site or stability 
of the PK protein.  This relationship between disruptive PKLR mutations to more severe symptoms 
and complications in PK deficiency has also been confirmed by data from the Pyruvate Kinase 
Deficiency Natural History Study (PKD NHS), a multicenter, international registry.6 With an 
improved understanding of the relationship between genotype and clinical features, genetic testing 
has been recommended to assist in determination of expected prognosis and development of an 
individualized monitoring plan. Recent consensus guidelines on the diagnosis of PK deficiency 
recommend diagnostic confirmation with genetic testing.5,21  
 
In this manuscript, we report the molecular characterization of 257 patients with PK deficiency 
enrolled in the PKD NHS. The study highlights the wide molecular heterogeneity of PK deficiency, 
including 45 novel variants reported in this cohort. The large number of patients enrolled 
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worldwide also allows a description of clinical features of the most common homozygous 
mutations.     
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The international PKD NHS was opened at 30 centres (United States (n=19), Canada (n=3), Italy 
(n=1), Czech Republic (n=1), Germany (n=5), Netherlands (n=1), Supplemental Table 1).  The 
study protocol was approved by the Institutional Review Board and/or Ethics Committee at each 
site, and all patients or their legal guardians, gave informed consent.  Patients were able to 
participate from afar by signed medical releases or were primarily followed at a centre approved to 
conduct the study.6   
 
Patients were eligible to be included in the registry study if they had a genetically confirmed 
diagnosis of PK deficiency with two identified PKLR mutations.  If patients had prior genetic 
testing which confirmed two pathogenic PKLR mutations, this was not repeated.  If prior genetic 
testing was not conducted or the results were not available, samples were sent for molecular 
analysis by Sanger sequencing (Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico 
Milan or Yale-New Haven Children’s Hospital).   
 
At the time of enrolment, patients’ medical records were reviewed retrospectively. Data collected 
included medical history, physical examination, and laboratory and radiologic studies. Clinical 
complications, including extramedullary hematopoiesis and pulmonary hypertension, were reported 
within the medical record and defined by individual clinical teams. Medical history missing from 
the medical records was obtained by patient recall, if known.  Transfusion data were collected from 
medical records. At all sites, except in Lancaster, Pennsylvania, data were only collected if obtained 
for clinical purposes. In Lancaster, Pennsylvania, in which all enrolled patients were Amish, 
additional laboratory and radiologic data were collected under a site-specific IRB-approved 
protocol. 
 
 Molecular analysis 
 
For the 119 patients who underwent sequencing through the study, the entire coding region and 
promoter of the PKLR gene were amplified by polymerase chain reaction (PCR) and automatically 
sequenced (ABIPRISM 310 Genetic Analyzer, Applied Biosystems, Warrington, UK) using the Big 
Dye Terminator Cycle Sequencing Kit.16  Large deletions were detected by long range PCR and 
separation on agarose gel.  Mutations were reported using the RPK cDNA sequence of the PKLR 
gene, with the A of the initiation ATG being assigned number +1 (Transcript refseq ID 
NM_000298.5).  Previously unreported novel mutations were defined as those not described by 
HGMD, 1000 Genomes, or ExAC databases. The new variants were classified according to the 
American College of Medical Genetic and Genomics (ACMG) standards and guidelines.22    
Expected pathogenicity was assessed by using the online prediction tools Polyphen2, Predict SNP 
(https://loschmidt.chemi.muni.cz/predictsnp1), and M-CAP (http://bejerano.stanford.edu/mcap).22-23   
Prediction analysis for splice site mutations was conducted by the web server tool Human Splice 
Finder (HSF3.1), using both MaxEnt and HSF algorithms24. 
 
Genotype categories and genotype-phenotype analysis 
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For this analysis, patients were categorized according to their genotype as follows: (a) 
missense/missense; (b) missense/non-missense; or (c) non-missense/non-missense mutations. Non-
missense pathogenic variants included nonsense, frameshift, in-frame small indels, large deletions, 
and splicing variants; missense mutations also affecting splicing were categorized as non-missense 
(i.e. p.R479H). Of the 257 patients with genotype data, 62 patients were excluded from the 
genotype-phenotype correlation analysis, including patients with three pathogenic variants (n=2) or 
promoter variants classified as uncertain significance (n=3) and patients who did not report clinical 
and demographical data (n=2). Patients from the Amish community (homozygous for the splicing 
mutation p.R479H, n=55) were also excluded from the main genotype-phenotype analysis. Thus, 
the genotype-phenotype analysis included 195 patients. The most common homozygous variants, 
p.R479H and p.R510Q, were analysed separately for an association between genotype and 
phenotype.  Additionally, the correlation between pregnancy outcomes and perinatal course of 
patients were separately analysed according to genotype groups. 
 
Transfusion status and iron overload 
 
Transfusion needs were classified into the following categories: (a) regularly transfused: ≥6 
transfusions within a 12-month period; (b) not regularly transfused: 1-5 transfusions within a 12-
month period; (c) not transfused: no transfusions. Iron overload at enrolment was defined as a 





Patient demographics, transfusion status, comorbid diagnoses and other disease characteristics were 
described with frequencies, proportions, medians, means, ranges and inter-quarter ranges (IQR) as 
appropriate to sample size, overall, by genotype category, and p.R510Q and p.R486W variant 
subgroups. Differences between genotype categories were identified using a Fisher’s exact test or a 
Wilcoxon rank-sum test.  Sample sizes are presented for those with known data available for each 
variable. To quantify the degree of similarity between siblings, the intra-cluster correlation 
coefficient (ICC) was calculated for clinical factors. ICC (range: 0 to 1 in human studies) compares 
the variance within sibling clusters to the variance between sibling clusters and tends to be larger 
for small clusters. ICCs and their 95% confidence intervals (CI) were computed using the SAS 
ICC9 macro.25   Data analyses were performed using SAS software 9.4 (SAS Institute Inc., Cary, 
NC, USA).  Sample sizes are presented for those with known data available for each variable.  P-






The PKD NHS enrolled 278 patients with PK deficiency from June 2014 through April 2017.  The 
clinical characteristics of the cohort have been previously described.6,9 After exclusion of 21 
ineligible patients in whom two pathogenic PKLR mutations could not be demonstrated, 257 
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eligible participants are reported herein. Baseline demographic information and clinical 
complications, available in 255 patients, are presented overall and by genotype category (Table 1).  
  
Spectrum of mutations 
 
Molecular characterization confirmed the wide genetic heterogeneity of PK deficiency. Overall, 
127 different mutations were detected: 84 missense, 20 premature stop codons (7 nonsense and 13 
frameshift due to small indels mutations), and 11 splicing mutations; moreover, 5 large deletions, 4 
in-frame indels, and 3 promoter variants were detected (Supplementary Tables 2-4). Most patients 
(85%) had at least one missense mutation.  Two patients had 3 different mutations. Excluding the 
Amish cohort, the two most frequent mutations were p.R510Q and p.R486W accounting for 23% 
(83/354) and 9% (31/354) of unrelated alleles, respectively. Additional 10 mutations were detected 
in unrelated patients with a frequency >1.4% each (Figure 1A).   
 
Out of the 177 unrelated patients, 35 had homozygous mutations (19 were homozygous for 
p.R510Q), 77 patients were compound heterozygous for two different missense mutations, and 48 
were compound heterozygous for one missense and one non-missense mutation. Seventeen patients 
were compound heterozygous for two non-missense mutations (Figure 1B). 
 
Thirteen patients carried large deletions, 11 of them were homozygous. The exact cut-off points 
were defined for the deletions in only 7 of these patients. In 6 unrelated patients, the reported 
mutation was c.1437-518_1618+440del, encompassing exons 10 and 11, which has been previously 
reported in patients with a Roma ethnic background4. In one patient, the reported mutation was 
c.283+1914_c.1434del5006, encompassing exons 3-11, which has been previously reported in 
patients with Asian ancestry.11  In the remaining 6 patients, reported deletions included exons 10-
11, exon 2-3, and another large deletion without precisely reported cut-off points.  
 
Forty-five variants, all predicted to be likely pathogenic or pathogenic following ACMG guidelines,  
have not been previously reported; among them were 28 missense, 2 stop codon, 6 frameshift, 3 in-
frame indel, 5 splicing, and 1 promoter mutation (Figure 2, Supplementary Table 5). Of the 257 
patients, 55 (21%) were found to have at least one new molecular variant.                   
               
Genotype-phenotype Associations 
 
Of the 195 patients in the genotype-phenotype analytic cohort, patient PKLR gene mutation types 
included: 113 (58%) missense/missense, 52 (27%) missense/non-missense, and 30 (15%) non-
missense/non-missense mutations (Table 1). As compared with patients with missense/missense 
(M/M) or missense/non-missense (M/NM) PKLR mutations, patients with non-missense/non-
missense (NM/NM) mutations have a lower hemoglobin level post-splenectomy (M/M and M/NM: 
8.7 g/dL range: 4.3-12.8, n=75; NM/NM: 8.1 g/dL, range: 6.5-9.7, n=21; p=0.009), higher number 
of lifetime transfusions (M/M and M/NM: 20, range: 1-516; NM/NM: 67, range: 3-363; p=0.0005), 
higher rate of iron overload (M/M and M/NM: 46%; NM/NM: 85%; p=0.0004), and higher rate of 
splenectomy (M/M and M/NM: 47%; NM/NM: 70%; p=0.03). The frequency of pulmonary 
hypertension and extramedullary hematapoiesis was highest in patients with non-missense/non-
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missense mutations (M/M and M/NM: 3.6% vs. NM/NM 12%; and M/M and M/NM: 2.7% vs. 
NM/NM 10%, respectively). Other complications were of similar frequency between the groups 




Of the 257 patients, 88 had one or more siblings who were also in this study.  These 88 comprised a 
total of 38 families, with a minimum of two siblings and a maximum of five siblings per family. 
There were 29 families of 2 affected siblings; 7 with 3 affected siblings; one with 4 affected 
siblings, and one with 5 affected siblings.  
 
With ICCs ranging from 0.4-0.61, about the same degree of similarity exists within sibling clusters 
as it does between sibling clusters, in terms of hemoglobin, total bilirubin, splenectomy, and 
cholecystectomy (Supplemental Table 6).  
 
In most of the families (28/38, 74%), siblings were homogeneous in terms of their splenectomy and 
transfusion status. Of these 28 homogeneous families, 10 families were not splenectomized and not 
on regular transfusion, 17 families were splenectomized but not on regular transfusion, one family 
was splenectomized and receiving regular transfusion. 
 
Genotype and Perinatal and Pregnancy Outcomes 
 
The in utero and perinatal course of patients with PK deficiency was not significantly different 
based on genotype (Table 2).  Of patients documented to have had perinatal complications and/or 
treatment, the rate of in utero transfusions was not significantly different between the mutation 
groups: M/M 46% (12/26), M/NM 56% (8/15), and NM/NM 40% (4/10). Among patients for 
whom data were available, the rate of treatment with exchange transfusions was also not different 
between the groups: M/M 42% (34/80), M/NM 43% (17/40), and NM/NM 43% (9/21).  There were 
29 pregnancies in women with M/M mutations, 13 with M/NM, and 7 with NM/NM. The rate of 
full-term healthy births was not different between the groups (Table 2).  However, management 
during pregnancy was significantly different by genotype. Only 42% of pregnant women with M/M 
mutations were transfused during pregnancy, while 100% of those with NM/NM mutations were 
transfused during pregnancy. 
 
Homozygous p.R479H variant  
 
All 55 Amish patients were homozygous for the p.R479H PKLR variant. Most patients were 
diagnosed soon after birth based on clinical symptoms in the setting of the high prevalence of PK 
deficiency in the Amish community, with a median age of diagnosis of 2 days (range 0 days-10 
years, n=52), and 53% required exchange transfusion after birth (Supplemental Table 7). In the 12-
month period prior to enrolment, one Amish patient (2%) was regularly transfused, four patients 
(7%) received 1-5 transfusions, and 50 (91%) were not transfused. Of the 13 Amish women who 
had been pregnant, 46% (6/13) required transfusions during pregnancy, similar to the M/M group.   
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Most patients were regularly transfused until splenectomy; the rate of splenectomy was higher in 
this subgroup [93% (51/55)] than it was in patients without a homozygous p.R479H variant [50% 
(99/200); p≤0.0001]. The median post-splenectomy hemoglobin was 9.4 g/dl (range: 8-11.2, n=51). 
The median maximum ferritin was 616 ng/ml (range 126-3258) with 33% (14/42) of patients 
meeting criteria for iron overload at enrolment.  Although the rate of cholecystectomy in this 
subgroup [27% (15/55)] was lower than it was in patients without a homozygous p.R479H variant 
[43% (86/200); p=0.04], the rate of gallstones [44% (24/54)] was similar to those without a 
homozygous p.R479H variant [45% (86/195); p=1.0]. No differences were observed in 
homozygous p.R479H patients and patients without homozygous p.R479H variant regarding the 
rate of pulmonary hypertension [2% (1/54) vs 3% (7/184); p=0.7], whereas 33% of the group had 
extramedullary hematopoiesis, significantly higher than patients without the homozygous p.R479H 
variant [5% (8/168); p<0.0001]. 
 
Homozygous p.R510Q variant   
 
Within the homozygous p.R510Q group (n=19), the median age at diagnosis was 0.2 years (range 
0-48 years; n=18, Supplemental Table 8). The median hemoglobin of those splenectomized and not 
regularly transfused was 11.3 g/dl (range: 9.9-11.5, n=5) consistent with a high rate of complete 
hemoglobin response to splenectomy in patients with this genotype.  However, the rate of 
splenectomy in this cohort (37%) was also lower than in patients without the homozygous p.R510Q 
variant [61% (143/236); p=0.053]. Within the 12-month period prior to enrolment, two patients 
(11%) received regular transfusions, six patients (32%) received 1-5 transfusions, and 11 patients 
(58%) were not transfused. 
 
The 37% (7/19) rate of cholecystectomy was similar to patients without the homozygous p.R510Q 
variant [40% (94/236); p=1.0].  The median maximum ferritin level was 896 ng/ml (range 64-5698, 
n=8), similar to other patients in the M/M group [573 ng/ml (range 31-9679, n=67); p=0.6].  The 
rate of iron overload [38% (3/8)] was also similar to other patients in the M/M group [43% (30/69); 
p=1.0].  
 
Patients with a p.R510Q variant in the compound heterozygote state with a non-missense mutation 
(n=19) had a more severe clinical presentation than the homozygous p.R510Q cohort and was 
similar to the NM/NM cohort.  




PK deficiency is a rare congenital hemolytic anemia with a diverse phenotype and wide spectrum of 
severity.  The PKD NHS is an international registry of patients with PK deficiency which has led to 
an improved understanding of the clinical spectrum and current management strategies for patients 
with this disorder.6  In the present study, we report the highly diverse molecular features of this 
cohort and an in depth description of the observed genotype-phenotype correlations.    
  
This study confirms the wide genetic heterogeneity of PK deficiency with 127 different pathogenic 
variants in this cohort, 45 of which have not been previously reported.  There are now 371 
identified pathogenic PKLR gene variants associated with PK deficiency 
(https://grenada.lumc.nl/LOVD2/mendelian_genes/home.php). Of the 45 new variants, 43 have been 
never reported in HGMD or other databases; the remaining two, p.A31V and p.D339Y, are reported 
with a MAF ExAc frequency lower than 10-4 - 10-5, drastically below the cut-off of the definition of 
polymorphism. All of the missense variants were predicted as possibly or likely pathogenic using 
Polyphen2, M-CAP or other in silico tools, and were associated with reduced PK enzyme activity.  
All of the splicing mutations, except one, affected the invariant dinucleotides of the intron 
bordering sequences.  The variant c.966(-9)A>G was also predicted to affect splicing by Human 
Splicing Finder 3.124 and classified as likely pathogenic,  because it was identified at homozygous 
level in a patient with reduced PK activity and congenital hemolytic anemia.  
 
The mutations were distributed throughout the PKLR gene and affected all exons; however, there 
was a higher frequency of variants in exons 5, 8, 9 and 11 with 9.1%, 9.3%, 10.5% and 16.4% of 
the nucleotides affected, respectively. Exon 11 had the highest number of mutated alleles due to 
presence of the common mutations p.R486W and p.R510Q. Both these variants involve an arginine 
residue and are located in C domain responsible for tetramer stability. Of note, 10 out of the 23 
amino acid substitutions identified in this domain involve an arginine residue.10 Despite the 
increased frequency of variants in certain exons, the molecular diversity of PK deficiency 
underlines the need to analyze the entire PKLR gene, without limiting the analysis to the most 
common variants that cover no more than 30% of the total number of mutated alleles.  
 
Among the 257 cases studied in this cohort, two unrelated patients carried three different mutations; 
two of them were non-missense and present in both patients (p.E241X and p.V276WfsX45), and 
the third in each was a missense mutation (p.R510Q and p.A495V). Although parent samples were 
not available for these two patients to define the inheritance of the variants, we hypothesize that 
both non-missense mutations were located on the same allele, in trans, to the missense mutation, 
thus resulting, at clinical level, as a missense/non-missense genotype. Given the lack of parent 
studies, these patients were not included in the genotype-phenotype analysis. In one of the two 
patients, anemia had been observed since birth with a post-splenectomy hemoglobin of 10.4 g/dl. 
The other patient also presented with anemia at birth and then has received regular transfusions 
with an intact spleen to date. The presence of two different variants transmitted on the same allele 
has already been reported in other patients26-29 and contributes to the wide molecular heterogeneity 
observed in PK deficiency but also might lead to a possible misdiagnosis of an affected patient with 
compound heterozygous mutations rather than a patient in the heterozygote state. 
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Despite sequencing all exons, intronic flanking regions, and the erythroid promoter of PKLR gene, 
patients with a clinical phenotype of PK deficiency and low PK enzyme levels are sometime found 
to have only one PKLR mutation or no mutations at all.5 Among the 278 initially enrolled 
participants in the PKD NHS, 21 were considered ineligible for this study due to the inability to 
demonstrate two pathogenic variants after the exclusion of large deletion performed by long range 
PCR. For some cases, unknown mutations may be in intronic or regulatory regions that are not 
covered by conventional diagnostic molecular techniques or that cannot be considered as 
pathogenic in the absence of functional tests.5,17 An example of such a case was published in which 
a deep intronic mutation (c.283+109C>T, intron 2) was coupled with missense mutation p.G332S 30  
Since an increasing number of pathogenic deep intronic mutations are being described across 
different disease conditions (α spectrinLEPRA  (SPTA1 c.4339-99C>T 31-33) and Androgen 
Insensitivity Syndrome (c2450-118A>G)),34 clinical molecular testing algorithms may have to be 
revised to include extended intronic regions, especially when only one missense mutation is 
identified in the first pass.   
 
The structural architecture of the PK molecule contributes to the heterogeneity of biochemical 
properties of the abnormal variants. PK is a tetramer with four identical subunits, each consisting of 
four structural domains.  Enzyme activation is thought to involve a combination of domain and 
subunit rotations coupled to alterations in the active site geometry.18 Patients with compound 
heterozygote variants of the same genotype may have different combinations of tetramers resulting 
from differences in the assembly of the molecule due to a variable amount of one monomer 
resulting from one mutated allele with respect to the other one. This hypothesis, together with the 
possible effect of yet unidentified genetic modifiers of the expression of PK, may explain the 
clinical variability seen among siblings with the same variants. 
 
In this cohort, 142 patients were compound heterozygotes, making genotype-phenotype correlations 
challenging.  Given the number of variants and patients who are compound heterozygotes, patients 
were stratified according to their type of mutations (missense/missense, missense/non-missense, 
non-missense/non-missense). However, there are some limitations to this categorization.  For 
example, some missense mutations may result in marked protein instability or functional inactivity, 
or, although not directly involved in splicing consensus sequences, may result in altered splicing. 
On the other hand, some non-missense variants may not have a significant impact on the protein 
structure.   
 
 The study showed that patients with two non-missense mutations had lower hemoglobin levels 
post-splenectomy, higher numbers of lifetime transfusions, higher rates of iron overload, and higher 
rates of splenectomy.  Although patient and provider management decisions determine transfusion 
and splenectomy status, these data confirm previous observations that patients with two non-
missense mutations tend to have a more severe clinical phenotype, including serious but rare 
complications, such as extramedullary hematopoiesis and pulmonary hypertension.  These 
complications were seen more frequently in patients with non-missense mutations or with missense 
mutations characterized by severely decreased protein stability, suggesting that these complications 
may be associated with absence or severely decreased PK protein. 19  
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The observed genotype-phenotype associations are consistent with previous reports.12 Due to the 
intrinsic difficulties of examining the relationship between genotype-phenotype in PK deficiency, 
future studies should consider studying the relationship between residual PK protein level and 
clinical phenotype.  Indeed, studies have shown that there is a relationship between residual PK 
protein and hemoglobin response to an oral PK activator in clinical development. 35   
 
Surprisingly, there was no association identified between PKLR genotype and the frequency of 
complications in utero or in the newborn period, suggesting that the clinical presentation at birth is 
not predictable, even among siblings.  Pregnancy was similarly tolerated across genotypes in 
women with PK deficiency.  Pregnancy outcomes were not different among genotype groups; 
however, all women with two non-missense PKLR variants required transfusion support during 
pregnancy, whereas only 43% of women with two missense mutations required transfusions.  This 
is consistent with the general finding that patients with two non-missense variants tend to require 
more transfusions and have more iron loading than the other variant groups.   
 
The clinical features of the two largest groups of patients with homozygous genotypes were 
analysed separately, homozygote p.R510Q (n=19) and homozygote p.R479H (n=55).  Most of the 
patients homozygous for the p.R479H variant, seen in the Amish population, presented with 
symptoms soon after birth leading to a rapid diagnosis in early infancy. The rate of splenectomy, 
93%, was the highest in the homozygous p.R479H cohort, likely related to an attempt to limit the 
time period of patients’ requirement for regular transfusions.  These patients also had the highest 
rate of certain complications, including extramedullary hematopoiesis.  The severity of the clinical 
phenotype correlates with the severity of the effect of this variant, causing abnormal splicing, 
consistent with what has been observed in prior studies. 3,36   
 
p.R510Q is considered the most common variant in the Caucasian population with a reported allelic 
frequency of 0.7 x103 (Gnom AD https://gnomad.broadinstitute.org/) and was detected in 23% of 
the mutated unrelated alleles in this series of patients.  The observation of its association with the 
haplotype [(ATT)14/(T)10/C1705/C1738/C1992] supports the hypothesis of a single origin of this 
variant.10  The homozygous p.R510Q cohort had clinical features similar to the M/M group with 
prior splenectomy in only 37% but generally with a robust post-splenectomy hemoglobin response 
to the treatment (Hb level after splenectomy 11.3 g/dl in homozygous p.R510Q group vs. 9.2 g/dl in 
the M/M group).  Of note, patients with a p.R510Q in the compound heterozygote state with a non-
missense mutation (n=19) had a more severe clinical presentation than the homozygous p.R510Q 
cohort and was similar to the NM/NM cohort. This finding suggests that the drastic protein 
instability caused by the p.R510Q mutation may result in worsening of severity when associated 
with variants with a different drastic effect on the protein. 18,19   
 
In addition to the limitations of the mutation characterization groups, other limitations of this study 
include its retrospective observational design, the lack of genome-wide data to account for 
relatedness of patients, and the limited number of patients despite the global effort and number of 
sites.  In addition, clinical, laboratory, and radiologic monitoring and treatments, including 
transfusions and splenectomy, varied and may have been biased by provider, hospital, and region.  
The genotype-phenotype relationships in PK deficiency described here underscores the importance 
of genetic testing not only to confirm the diagnosis but also to discuss prognosis and establish a 
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monitoring plan for patients.5 The findings from the in depth evaluation of the cohorts with 
common homozygous variants as well as siblings suggest that non-genotype factors, such as degree 
of splenomegaly, splenic conditioning, other red cell variants, and co-inherited variants in iron and 
bilirubin metabolism and different treatment approaches may also be significant contributors to the 
clinical phenotype. Future analyses aimed at describing this variation may reduce the clinical 
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FIGURE LEGENDS  
 
Figure 1.  Spectrum of PKLR mutations in the PKD Natural History Study.   
Figure 1A shows the frequency of all of the detected unrelated mutations.  The Amish cohort is 
excluded from this figure.   
Figure 1B shows frequency of patients with missense/missense (M/M), missense/non-missense 
(M/NM), and non-missense/non-missense (NM/NM) mutations. 
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n % or median (range) n 
% or median 
(range) n 
% or median 
(range) n 
% or median 
(range) 
 
Gender, Male 125 49% 66/113 58% 30/52 58% 14/30 47% 0.3 
Age at diagnosis (y) (median, range) 244a 0.4 (0-60.3) 107 1.3 (0-60.3) 50 0.7 (0-42.3) 30 0.5 (0-10.9) 0.03 
Age at enrolment (y) (median, range) 255 19.0 (0.1-69.9) 113 17 (0.1-68.5) 52 17.5 (0.6-69.9) 30 14.6 (0.2-50.3) 0.3 
Race, Caucasian 236 93% 103/113 91% 48/52 92% 25/30 83% 0.1 
Ethnicity, Hispanic 18/247 7% 8/108 7% 6/50 12% 4/30 13% 0.5 
Number of lifetime transfusions  
(median, range) 
191 18 (1-516) 81 16 (1-486) 38 25 (1-516) 28 67 (3-363) 0.0005 
Transfusion Status in the last 12 months 
Regularly Transfused (≥6) 
Not Regularly Transfused (1-5) 


































Hemoglobin (g/dl) (median, range) 252 9 (4.3-14.2) 111 9.5 (4.3-13.9) 51 8.7 (6.4-14.2) 30 7.9 (6.2-9.7) <0.0001 
Hemoglobin post-splenectomy (g/dl) 148 8.8 (4.3-12.8) 49 9.2 (4.3-12.3) 26 8.5  (6.4-12.8) 21 8.1 (6.5-9.7) 0.009 
Hemoglobin change from pre-
splenectomy to post-splenectomy (g/dl) 
72 1.6 (-5.5-4.9) 27 1.6 (-3.3-4.5) 13 1.6 (-5.5-3.4) 13 1 (-2.8-2.7) 0.3 
Transfusion status post-splenectomy 
Regularly Transfused (≥6) 
Not Regularly Transfused (1-5) 
Not Transfused (0) 
 
17/146  
23/146   
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Splenectomized 150/255 59% 50/113 44% 27/52 52% 21/30 70% 0.03 
Gallstones 112/249 45% 49/109 45% 26/51 51% 12/30 40% 0.6 
Maximum ferritin (mg/dl) (median, 
range) 
Regularly Transfused (≥6) 
Not Regularly Transfused (1-5) 






































Iron Overload  
 
Regularly Transfused (≥6) 
Not Regularly Transfused (1-5) 














































Extramedullary Hematopoiesis 23/213 11% 5/94 5% 0/43 0% 3/26 12% 0.1 
Pulmonary Hypertension 8/238 3% 3/101 3% 1/49 2% 3/29 10% 0.09 
Leg Ulcers 4/241 2% 1/104 1% 2/49 4% 1/29 3% 0.5 
Aplastic Crises 34/246 14% 15/110 14% 9/50 18% 4/28 14% 1 
Liver Cirrhosis 8/241 3% 2/107 2% 2/48 4% 1/28 4% 0.6 
Bone Fracture 41/240 17% 18/103 17% 8/49 16% 6/29 21% 0.6 
Endocrine Dysfunction 
Thyroid disease 



























































*Countries of enrolment: United States (155), Germany (31), Italy (25), Netherlands (23), Canada (14), Czech Republic (7).  **Patients with R479H mutation are excluded from the 
missense/missense cohort.  ***p-values are obtained by comparing Missense/Missense and Missense/non-Missense combined group vs non-missense/ non-missense using Wilcoxon 
rank-sum test for continuous variables (age, hemoglobin, maximum ferritin, number of lifetime transfusions variables), Cochran and Armitage trend test for ordinal variables 
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(transfusion status in the last 12 months, transfusion status post-splenectomy), and Fisher’s exact test for binary variables (gender, race, ethnicity, splenectomized, gallstones, iron 
overload, extramedullary hematopoiesis, pulmonary hypertension, leg ulcers, aplastic crises, liver cirrhosis, bone fracture, and endocrine dysfunction variables).   
# comparing ferritin measurements between the missense/missense and missense/non-missense combined group vs non-missense/ non-missense using Wilcoxon rank-sum test in subsets 
of patients (subsets are: regularly transfused (≥6), not regularly transfused (1-5), not transfused (0) respectively)  
## comparing iron overload between the missense/missense and missense/non-missense combined group vs non-missense/ non-missense using Fisher’s exact test in subsets of patients 
(subsets are: regularly transfused (≥6), not regularly transfused (1-5), not transfused (0) respectively).  
N: Total number of patients enrolled overall; n: number of patients per demographic characteristic.  Age expressed as n, median (range) years; all other data expressed as n (%).  a11 
patients had unknown age at diagnosis. b255 out 257 PKD patients have reported demographical and clinical data and their data are recorded in the database; the denominators are less 
than 255 because some patients had unknown data. 
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Characteristics n n n  
Perinatal Complications/Treatment 






























 (data presented per pregnancy of 
affected woman with PKD)* 
 
Normal birth - Full-term 
Pre-maturity 
Transfusions during pregnancy 
n=29 pregnancies* 




















*Patients with known and available clinical data.  For each proportion calculated, the denominator is the number of patients or pregnancies with known data for 
that characteristic. 
** Comparing Missense/Missense to non-Missense/non-Missense group using Fisher exact test 
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